NCT05539053 is a NA clinical trial of N Acetylcysteine A in Chemotherapy-induced Peripheral Neuropathy, sponsored by Department of Medical Services Ministry of Public Health of Thailand.

Who is sponsoring NCT05539053?

NCT05539053 is sponsored by Department of Medical Services Ministry of Public Health of Thailand.

What drugs are being tested in NCT05539053?

Interventions in NCT05539053: N Acetylcysteine A, N Acetylcysteine B.

What condition does NCT05539053 study?

NCT05539053 studies Chemotherapy-induced Peripheral Neuropathy.

Is NCT05539053 still recruiting?

NCT05539053 is currently completed. Last updated 25 January 2024.

Last reviewed 2024-01-25 · How we verify

NCT05539053

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of NAC for the Prevention and Relief of PIPN in Women With Ovarian, Tubal, and Peritoneal Cancer

Completed NA Last updated 25 January 2024

What this trial tests

NA trial testing N Acetylcysteine A in Chemotherapy-induced Peripheral Neuropathy in 60 participants. Completed in 30 December 2023.

Timeline

1 November 2022

Primary endpoint
30 November 2023

30 December 2023

Quick facts

Lead sponsor	Department of Medical Services Ministry of Public Health of Thailand
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	60
Start date	1 November 2022
Primary completion	30 November 2023
Estimated completion	30 December 2023
Sites	1 location across Thailand

Drugs / interventions tested

N Acetylcysteine A — full drug profile →
N Acetylcysteine B — full drug profile →

Conditions studied

Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →

Sponsor

Department of Medical Services Ministry of Public Health of Thailand

Who can join

18 and older, female only, with Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ovarian cancer is third most common gynecologic cancer in Thai woman, treatment including surgery followed by chemotherapy. Patient usually received paclitaxel every 3 week for 6 cycles, paclitaxel induce peripheral neuropathy is common dose dependent side effect which can disturb quality of life, result in chemotherapy dose reduction or discontinuation leading to poor prognosis and decreased survival Mechanism of PIPN including inflammation, promotion of microtubule polymerization and inhibition of depolymerization, and oxidative stress N-acetylcysteine is acetylated form of l-cysteine, might reduce oxidative stress. NAC can restore glutathione level, which is potent natural antioxidant. NAC might reduce PIPN

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers.
Liang X, Weng J, You Z, Wang Y, et al · · 2025 · cited 50× · PMID 40847302 · DOI 10.1186/s12943-025-02375-x

Verify or expand the search:

Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy

Currently open trials in the same condition.

NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting

Other Department of Medical Services Ministry of Public Health of Thailand trials

Trials by the same sponsor.

NCT06665737 — Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients · Phase 4 · not yet recruiting
NCT06763575 — Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy · NA · recruiting
NCT06860659 — Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient With Moderate to Severe Dry Eye · Phase 4 · enrolling by invitation
NCT06525870 — Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Control · Phase 2 · enrolling by invitation
NCT06436833 — Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Gl · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05539053 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Department of Medical Services Ministry of Public Health of Thailand
Last refreshed: 25 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05539053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing